Literature DB >> 10369989

Assessment of osteosarcoma response to neoadjuvant chemotherapy: comparative usefulness of dynamic gadolinium-enhanced spin-echo magnetic resonance imaging and technetium-99m skeletal angioscintigraphy.

P Ongolo-Zogo1, P Thiesse, J Sau, C Desuzinges, J Y Blay, A Bonmartin, M Bochu, T Philip.   

Abstract

The aim of this work was to study and compare the usefulness of dynamic contrast-enhanced spin-echo MR imaging with high temporal resolution hydroxymethylene diphosphonate technetium-99 m skeletal angioscintigraphy in predicting the osteosarcoma histological response to neoadjuvant chemotherapy. Twelve patients with resectable osteosarcoma were prospectively monitored with dynamic MR imaging and skeletal scintigraphy before start of neoadjuvant chemotherapy, after two cycles of therapy and before surgery. Neoplasm signal intensity and activity intensity were plotted against time, and slopes were calculated for percentage increase over baseline values in the first minute. Stability and increase in slope values during or after chemotherapy were defined as a "radiological non-response". Changes in slopes were compared with the "histological response" (Huvos grading). At midpoint of the chemotherapy, these two imaging modalities failed in predicting final histological response. After the completion of the chemotherapy, these imaging modalities allowed the prediction of histological response with the same accuracy (91 %). In this series, dynamic MR imaging and technetium skeletal scintigraphy provide similar results regarding the prediction of final histological response during neoadjuvant chemotherapy; these results cannot be used to modify the therapeutic protocol at midpoint of chemotherapy; these imaging tools predict accurately the histological response at the end of chemotherapy. These latter results may permit anticipation of the adjuvant chemotherapy strategy during decalcification procedures in resected osteosarcoma and thus to monitor chemotherapy in non-surgical osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10369989     DOI: 10.1007/s003300050765

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  9 in total

1.  A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy.

Authors:  Fariba Navid; Victor M Santana; Michael Neel; M Beth McCarville; Barry L Shulkin; Jianrong Wu; Catherine A Billups; Shenghua Mao; Vinay M Daryani; Clinton F Stewart; Michelle Kunkel; Wendene Smith; Deborah Ward; Alberto S Pappo; Armita Bahrami; David M Loeb; Jennifer Reikes Willert; Bhaskar N Rao; Najat C Daw
Journal:  Int J Cancer       Date:  2017-07-03       Impact factor: 7.396

2.  Value of diffusion-weighted images in differentiating mid-course responders to chemotherapy for osteosarcoma compared to the histological response: preliminary results.

Authors:  C Baunin; G Schmidt; K Baumstarck; C Bouvier; J C Gentet; A Aschero; A Ruocco; B Bourlière; G Gorincour; C Desvignes; N Colavolpe; G Bollini; P Auqier; P Petit
Journal:  Skeletal Radiol       Date:  2012-02-09       Impact factor: 2.199

3.  Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential ¹⁸F-FDG PET/CT and MRI.

Authors:  Byung Hyun Byun; Chang-Bae Kong; Ilhan Lim; Byung Il Kim; Chang Woon Choi; Won Seok Song; Wan Hyeong Cho; Dae-Geun Jeon; Jae-Soo Koh; Soo-Yong Lee; Sang Moo Lim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-21       Impact factor: 9.236

Review 4.  Percent slope analysis of dynamic magnetic resonance imaging for assessment of chemotherapy response of osteosarcoma or Ewing sarcoma: systematic review and meta-analysis.

Authors:  Tadahiko Kubo; Taisuke Furuta; Muhammad P Johan; Nobuo Adachi; Mitsuo Ochi
Journal:  Skeletal Radiol       Date:  2016-05-26       Impact factor: 2.199

5.  Triple-phase contrast-enhanced MRI for the prediction of preoperative chemotherapeutic effect in patients with osteosarcoma: comparison with (99m)Tc-MIBI scintigraphy.

Authors:  Hiroshi Wakabayashi; Junko Saito; Junichi Taki; Nanako Hashimoto; Hiroyuki Tsuchiya; Toshifumi Gabata; Seigo Kinuya
Journal:  Skeletal Radiol       Date:  2015-09-18       Impact factor: 2.199

Review 6.  Imaging of malignant tumours of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment.

Authors:  Hervé Brisse; Liliane Ollivier; Véronique Edeline; Hélène Pacquement; Jean Michon; Christophe Glorion; Sylvia Neuenschwander
Journal:  Pediatr Radiol       Date:  2004-04-22

7.  Colour Doppler ultrasound predicts chemotherapy response, but not survival in paediatric osteosarcoma.

Authors:  Jos A M Bramer; Feikje M Gubler; Mario Maas; Hans Bras; Jan de Kraker; Jan W van der Eijken; Gerard R Schaap
Journal:  Pediatr Radiol       Date:  2004-05-18

8.  Evaluation of tumor blood flow in musculoskeletal lesions: dynamic contrast-enhanced MR imaging and its possibility when monitoring the response to preoperative chemotherapy-work in progress.

Authors:  Makoto Kajihara; Yoshifumi Sugawara; Kenshi Sakayama; Keiichi Kikuchi; Teruhito Mochizuki; Kenya Murase
Journal:  Radiat Med       Date:  2007-04-27

9.  Effects of neoadjuvant chemotherapy on image-directed planning of surgical resection for distal femoral osteosarcoma.

Authors:  Kevin B Jones; Peter C Ferguson; Brian Lam; David J Biau; Sevan Hopyan; Benjamin Deheshi; Anthony M Griffin; Lawrence M White; Jay S Wunder
Journal:  J Bone Joint Surg Am       Date:  2012-08-01       Impact factor: 5.284

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.